Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 321.56M | 331.31M | 323.37M | 708.36M | 432.29M |
Gross Profit | 51.00M | 29.89M | 32.55M | 93.60M | 96.31M |
EBITDA | -33.61M | -74.53M | -69.08M | 17.72M | 41.06M |
Net Income | -45.24M | -94.10M | -93.74M | 4.64M | 21.04M |
Balance Sheet | |||||
Total Assets | 194.09M | 214.32M | 317.83M | 366.70M | 280.08M |
Cash, Cash Equivalents and Short-Term Investments | 71.66M | 80.35M | 154.02M | 174.83M | 104.89M |
Total Debt | 47.73M | 31.13M | 26.48M | 25.18M | 25.43M |
Total Liabilities | 120.81M | 94.35M | 116.97M | 73.21M | 109.08M |
Stockholders Equity | 71.14M | 116.13M | 195.02M | 283.11M | 161.18M |
Cash Flow | |||||
Free Cash Flow | -27.10M | -77.18M | -22.75M | -24.73M | 17.31M |
Operating Cash Flow | -14.05M | -75.58M | -18.46M | 262.00K | 31.12M |
Investing Cash Flow | -326.00K | 16.46M | -8.36M | -16.77M | -10.98M |
Financing Cash Flow | 5.68M | 906.00K | 54.00K | 92.84M | -4.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | HK$628.16M | 19.67 | -8.91% | 1.75% | 169.20% | ― | |
57 Neutral | £4.68B | 8.52 | -61.44% | 496.52% | 33.02% | 4.62% | |
55 Neutral | HK$142.00M | ― | -48.20% | ― | -4.57% | 52.37% | |
49 Neutral | HK$757.69M | ― | ― | ― | ― | ||
49 Neutral | HK$757.69M | ― | ― | ― | ― | ||
46 Neutral | HK$41.46M | ― | -9.43% | ― | -3.12% | -2869.57% | |
45 Neutral | HK$5.06B | ― | -2.97% | ― | 11.00% | 56.87% | |
44 Neutral | HK$1.36B | ― | -18.19% | ― | -24.50% | -93.44% | |
44 Neutral | HK$1.36B | ― | -18.19% | ― | -24.50% | -93.44% |
Mediwelcome Healthcare Management & Technology Inc. has successfully completed the placement of 40 million new shares, raising approximately HK$16 million in gross proceeds. The funds will be used for general working capital, and the placement has slightly altered the company’s shareholding structure without any placee becoming a substantial shareholder.
Mediwelcome Healthcare Management & Technology Inc. has issued a supplemental announcement regarding its 2024 Annual Report, specifically addressing the status of its RSU Scheme. The company clarified that no RSUs were granted or agreed to be granted during 2024, and the number of unvested RSUs for employees remained at zero throughout the year. This announcement does not affect other information in the 2024 Annual Report, indicating stability in the company’s reporting and operations.
Mediwelcome Healthcare Management & Technology Inc. announced the successful passing of all proposed resolutions at its Annual General Meeting held on June 25, 2025. The resolutions included the re-election of directors, re-appointment of auditors, and granting of mandates for share issuance and repurchase, all of which were unanimously approved by shareholders, indicating strong support for the company’s strategic direction.
Mediwelcome Healthcare Management & Technology Inc. has announced a placement of new shares under a general mandate, involving up to 40 million shares at a price of HK$0.40 per share. This move is expected to raise approximately HK$16 million in gross proceeds, with net proceeds of around HK$15.45 million intended for general working capital. The placement represents a significant portion of the company’s shares and is offered at a discount to recent trading prices, indicating a strategic effort to bolster financial resources.
Mediwelcome Healthcare Management & Technology Inc. announced a capital reduction for one of its subsidiaries, the Target Company, which will see Beijing Medi Healthcare, a group entity, reduce its registered capital by approximately RMB3.1 million, equating to 51% of the Target Company’s existing capital. This move will result in Beijing Medi Healthcare ceasing to hold any interest in the Target Company, leading to the exclusion of the Target Company’s financial results from Mediwelcome’s consolidated financial statements. The capital reduction is deemed a discloseable transaction under Hong Kong’s listing rules, and the consideration for the reduction was set at RMB7.0 million, based on an independent valuation reflecting market conditions.
Mediwelcome Healthcare Management & Technology Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Beijing. The meeting will address several key resolutions, including the re-election of directors, the re-appointment of the company’s auditor, and the approval of a general mandate for the directors to issue additional shares. These resolutions are aimed at strengthening the company’s governance and operational capabilities, potentially impacting its market position and shareholder value.
Mediwelcome Healthcare Management & Technology Inc. has established a Nomination Committee to enhance its corporate governance structure. The committee, primarily composed of independent non-executive directors, is tasked with reviewing the board’s composition and recommending qualified candidates for directorships. This move is expected to strengthen the company’s strategic alignment and ensure diversity and expertise within its leadership.